Superworth

Beam Therapeutics profit margin BEAM

Gross, operating and net profit as a share of revenue over the last twelve months, from 2023.

Net margin, 12 months
−54.7%
Peer median
22.9%

Over the twelve months to Jun 30, 2026, Beam Therapeutics kept −54.7% of its revenue as net profit.

The median for 10 biotech stocks of a similar size is 22.9%.

Profit margin over time

OperatingNet

Open the interactive chart, with overlays and comparisons

Fiscal year by fiscal year

Fiscal yearNet marginOperating margin
FY2025−56.5%n/a
FY2024n/an/a
FY2023−35.1%−46.7%
FY2022n/an/a
FY2021n/an/a
FY2020n/an/a
FY2019n/an/a

Quarter by quarter

QuarterEndedNet margin, 12 monthsChange on a yearOperating margin
Q2 FY26−54.7%n/an/a
Q1 FY26−39.6%n/an/a
Q4 FY25−56.5%n/an/a
Q3 FY25n/an/an/a
Q2 FY25n/an/an/a
Q1 FY25n/an/an/a
Q4 FY24n/an/an/a
Q3 FY24−41.1%n/a−52.2%
Q2 FY24−40.6%n/a−52.3%
Q1 FY24−37.3%n/a−50.3%
Q4 FY23−35.1%n/a−46.7%
Q3 FY23n/an/an/a

Against its peers

Companies in Biotechnology nearest Beam Therapeutics' size, closest first, today.

CompanyProfit margin
BEAMBeam Therapeutics−54.7%
ADMAAdma Biologics33.0%
VCELVericel7.9%
MGTXMeiraGTx19.9%
KRYSKrystal Biotech54.8%
RGENRepligen5.3%
TECHBIO-TECHNE15.0%
HALOHalozyme Therapeutics24.9%
NBIXNeurocrine Biosciences20.9%
EXELExelixis35.3%
INCYIncyte27.7%
Peer median22.9%

Where Beam Therapeutics ranks

What the profit margin tells you

Profit as a share of revenue at three levels: gross (after making the product), operating (after running the business) and net (after everything, including tax and interest).

Compare within an industry. 10% is superb for a retailer and poor for a software company.

More on Beam Therapeutics

Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.